RAPP - CIK 0002012593
The table below shows Rapport Therapeutics, Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$87.47M | -$64.83M | -$27.18M |
| Capital expenditure | $616.00K | $2.40M | $1.64M |
| Investing cash flow | -$187.47M | -$170.14M | -$78.86M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $270.79M | $221.63M | $145.14M |
Rapport Therapeutics, Inc. reported operating cash flow of -$87.47M for fiscal year 2025. That is down 34.9% from -$64.83M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.